Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell transplantation for aplastic anemia.

George E Georges1, Rainer Storb

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle 98109-1024, USA. ggeorges@fhcrc.org

International Journal of Hematology
|April 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of horse anti-thymocyte globulin on graft-<i>versus</i>-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.

Haematologica·2026
Same author

Donor-derived del[20q] following allogeneic-hematopoietic cell transplantation: a case with 26-year follow-up and literature review.

Bone marrow transplantation·2026
Same author

Long-Term Outcomes of Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Subsequent cancers following non-myeloablative conditioning for allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2025
Same author

Canine Hematopoietic Cell Transplantation for Graft-Versus-Host Disease.

Methods in molecular biology (Clifton, N.J.)·2025

Bone marrow transplantation significantly improves survival for aplastic anemia patients. Advances in donor matching and conditioning regimens enhance outcomes for both sibling and unrelated donor transplants.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Aplastic anemia treatment has seen major survival improvements over decades.
  • Allogeneic bone marrow transplantation (BMT) is a primary therapy for aplastic anemia.
  • Outcomes for BMT have advanced due to improved conditioning and HLA typing.

Purpose of the Study:

  • To review the advancements in bone marrow transplantation for aplastic anemia.
  • To highlight the current standards of care and future directions in BMT for aplastic anemia.

Main Methods:

  • Review of current literature and clinical practices in bone marrow transplantation for aplastic anemia.
  • Analysis of survival rates and complications associated with different conditioning and immunosuppression protocols.

Related Experiment Videos

Main Results:

  • Allogeneic BMT with HLA-identical siblings yields approximately 90% long-term survival using specific conditioning and immunosuppression.
  • Unrelated donor BMT outcomes have improved with optimized preparative regimens and high-resolution HLA typing.
  • Early transplantation for patients with matched unrelated donors is recommended before further immunosuppression.

Conclusions:

  • Bone marrow transplantation is a highly effective treatment for aplastic anemia.
  • Continued research focuses on reducing conditioning regimen toxicity and managing graft-versus-host disease.
  • Future hematopoietic stem cell transplantation aims to improve engraftment reliability and minimize long-term effects.